Author + information
- Received October 30, 2002
- Revision received December 20, 2002
- Accepted January 24, 2003
- Published online May 21, 2003.
- Charles Antzelevitch, PhD, FACC*,* (, )
- Pedro Brugada, MD, PhD†,
- Josep Brugada, MD, PhD‡,
- Ramon Brugada, MD, FACC*,
- Jeffrey A Towbin, MD, FACC§ and
- Kolawanee Nademanee, MD, FACC∥
- ↵*Reprint requests and correspondence:
Dr. Charles Antzelevitch, Masonic Medical Research Laboratory, 2150 Bleecker Street, Utica, New York 13501, USA.
An intriguing new clinical entity characterized by ST-segment elevation in the right precordial electrocardiographic leads and a high incidence of sudden death in individuals with structurally normal hearts was described by Pedro and Josep Brugada in 1992. The past decade has witnessed an exponential rise in the number of reported cases and a dramatic proliferation of papers serving to define the clinical, genetic, cellular, ionic, and molecular aspects of this disease. The purpose of this brief review is to chronicle the historical highlights that have brought us to our present understanding of Brugada syndrome.
☆ This study was supported by grants from the National Institutes of Health (HL-47678 and HL-66169), American Heart Association, New York State Affiliate and National Center, Mapfre Foundation, Ramon Brugada Sr. Foundation, Doris Duke Charitable Foundation, and the Masons of New York State and Florida.
- Received October 30, 2002.
- Revision received December 20, 2002.
- Accepted January 24, 2003.
- American College of Cardiology Foundation